https://www.statnews.com/2021/12/02/some-experts-suggest-omicron-variant-may-have-evolved-in-an-animal-host/ Skip to Main Content STAT * * * Contribute * Subscribe * Log In Try STAT+ Today My Account * My Account * Billing * Log Out Try STAT+ Today My Account [ ] Search Cancel * Topics + Coronavirus + Health + Pharma + Biotech + Politics & Policy + Health Tech + In the Lab + Business + Artificial Intelligence + Vaccines + Health Disparities + Prescription Politics * Opinion + First Opinion + The Pharmalot View + Adam's Take + Matt's Take + Off the Charts * Team + Biotech & Pharma o Adam Feuerstein o Damian Garde o Matthew Herper o Meghana Keshavan o Kate Sheridan o Ed Silverman + Health Tech o Mario Aguilar o Erin Brodwin o Katie Palmer o Casey Ross + Politics o Rachel Cohrs o Lev Facher o Nicholas Florko + Health & Science o Eric Boodman o Helen Branswell o Elizabeth Cooney o Isabella Cueto o Olivia Goldhill o Andrew Joseph o Usha Lee McFarling o Megan Molteni o Jennifer Adaeze Okwerekwu o Nicholas St. Fleur + Team o View All * Events + STAT Events + Industry Events Calendar + 2021 STAT Summit + View all Summits + Webinars * Newsletters * Reports * Video * Podcasts + The Readout LOUD + First Opinion Podcast * * STAT+ + STAT+ Exclusive analysis of biotech, pharma, and the life sciences Learn More o The Latest o My Account + Topics o Biotech o Pharma o Policy o Health Tech o Business + Columns o Adam's Take o Matt's Take o The Pharmalot View + Tools o CRISPR Tracker o Drug Pricing Policy Cheat Sheet + Events o STAT+ Conversations o All STAT Events + Team o Biotech and Pharma o Health Tech o Politics and Policy o Health and Science Account * My Account * Billing * Subscribe * Log In * Help More * Contribute * Group Subscriptions Follow Us * * * * * Trending: Coronavirus Health First Opinion Biotech Health Some experts suggest Omicron variant may have evolved in an animal host * Helen Branswell By Helen Branswell Dec. 2, 2021 Reprints * * * * * * * * * [4966650745] Transmission electron micrograph of SARS-CoV-2 virus particles. NIAID/NIH * * * * * * * * * When Covid-19 variants arise, the accepted wisdom is that the constellation of mutations they contain developed in an immunocompromised person who contracted the virus and couldn't shake the infection. But some scientists have an alternative theory for where the latest variant of concern, Omicron, may have acquired the unusual mutations that stud its spike protein. They speculate the virus could have evolved in another animal species. The theory goes that some type of animal, potentially rodents, was infected with the SARS-CoV-2 virus sometime in mid-2020. In this new species, the virus evolved, accumulating roughly 50 mutations on the spike protein before spilling back over into people. advertisement Kristian Andersen, an immunologist at the Scripps Research Institute, is among those who has been raising the idea that Omicron may have emerged from a reverse zoonotic event. (A zoonotic event is when an animal pathogen starts to infect and spread among people. A reverse zoonosis is when such a virus passes back into an animal species.) advertisement STAT+: Exclusive analysis of biopharma, health policy, and the life sciences. "I know that most people think that these [come from] immunocompromised individuals, and I do think that that's plausible, but to be perfectly honest, I actually think this reverse zoonosis followed by new zoonosis seems more likely to me given just the available evidence of the really deep branch, and then the mutations themselves, because some of them are quite unusual," Andersen told STAT. "I don't think we should dismiss that possibility, because I think it's definitely on the table." A number of other scientists who study the evolution of viruses have told STAT they think the idea isn't out of the question. Some place more weight on the theory that variants develop in immunocompromised people, while others feel there isn't enough evidence at this point to favor one option over the other. "Personally, I think it's probably more likely it was circulating undetected, in an immunocompromised individual," Emma Hodcroft, a molecular epidemiologist at the Institute of Social and Preventive Medicine in Bern, Switzerland, said via email. Having said that, though, Hodcroft insisted that it is important to explore the hypothesis. "I would certainly consider it a plausible alternative hypothesis to the evolution during a persistent infection in a human," said Andrew Rambaut, a professor of molecular evolution at the Institute of Evolutionary Biology in Edinburgh. He cautioned that coming up with a definitive answer won't be quick. "I am not sure we will be in a position to say for sure for a while," Rambaut wrote in an email. One of the peculiar traits of SARS-2 underpins this thinking. It is what virologists describe as a promiscuous virus; it is capable of infecting a number of species. Dogs and house cats. Large cats. Mink. White-tailed deer. Given how easily the virus seems to jump from species to species, people studying it assume this list will grow. Newsletters Sign up for Daily Recap A roundup of STAT's top stories of the day. [ ] Please enter a valid email address. [Sign up]Privacy Policy Leave this field empty if you're human: [ ] The original virus that came out of Wuhan, China, in early 2020 did not infect rodents. But as variants -- Alpha, Beta, Delta -- started to emerge, those viruses could infect rodents. Robert Garry, a professor of microbiology and immunology at Tulane Medical School, has been tracking the SARS-2 mutations that have arisen. Seven are associated with rodent adaptation -- the changes that seemed to allow the virus to infect mice, rats, and related species. All seven of those mutations are in Omicron, Garry noted. He believes it's a toss-up whether the variant developed in an animal or a human host, but if it's the former, his bet would be on rodents. Getting a firm answer might require enormous luck. Scientists are looking at various animal species to see if they can be infected with SARS-2; were they to find viruses like Omicron in any, that would swing the needle. But Michael Worobey, a professor of evolutionary biology at the University of Arizona, thinks one could do some experiments on selected species of wild animals to see if they can be infected and if, when infected, similar patterns of viral evolution occur. Studying the molecular clock of viruses that spread in animals -- looking at the speed at which they evolve and comparing it to SARS-2 evolution in humans -- could also provide some clues, said Worobey, who initially thought Andersen's idea was not impossible, but not the likeliest of explanations for Omicron. After hearing details of the explosive outbreak in white-tailed deer, he's rethinking the idea. For Worobey, the question is whether any animal species can become chronically infected with SARS-2 -- in effect, whether there are animal species in which SARS-2 lingers in the way it does in immunocompromised people. That could put positive selective pressure on the virus -- in other words give it an incentive to mutate to stay ahead of the animal's immune response. "It does move my thinking in terms of Omicron possibly having come from a reservoir, if there are [animal] reservoirs that do chronic infections," he said. Part of what leads Andersen to wonder about an animal source is the fact that the variant traces back to viruses that were spreading over a year ago. "That in itself you need to be able to explain," he said. Angela Rasmussen, a coronavirus virologist at the University of Saskatchewan's Vaccine and Infectious Disease Organization, agreed. "I think it's pretty obvious to everybody ... that this virus has been on an independent evolutionary track for quite some time and it's very surprising, which to me just kind of goes back to say well, the idea that this could be ... plausible," she said. Regardless of whether this variant emerged in another species or not, given SARS-2's ability to jump species, it is possible the world will face animal-derived variants in the future, Garry warned. The upshot of that? "We're going to have to keep tweaking the vaccines." * * * * * * * * * About the Author Reprints Helen Branswell Helen Branswell Senior Writer, Infectious Disease Helen covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. @HelenBranswell Tags Coronavirus infectious disease Create a display name to comment This name will appear with your comment [ ] There was an error saving your display name. Please check and try again. [Continue] Trending SARS-CoV-2 virus particle First case of Omicron coronavirus variant identified in the... First case of Omicron coronavirus variant identified in the U.S. [] A reason for optimism on Omicron: Our immune systems... A reason for optimism on Omicron: Our immune systems are not blank slates vaccine silhouette Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and... Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson Recommended SARS-CoV-2 virus particle First case of Omicron coronavirus variant identified in the... First case of Omicron coronavirus variant identified in the U.S. [] Listen: Who owns your health data -- and why... Listen: Who owns your health data -- and why you should care HIV stigma Stigma, not science, is the biggest barrier to ending... Stigma, not science, is the biggest barrier to ending the HIV epidemic Recommended Stories SARS-CoV-2 virus particle Health First case of Omicron coronavirus variant identified in the U.S. By Andrew Joseph Casonya "Sonya" Slone Health Her husband died by suicide. She sued his pain doctors -- a rare challenge over an opioid dose reduction By Andrew Joseph advertisement [330x400-00] Health Injecting cancer patients with genetically engineered viruses could be a 'rock star' therapy. Why hasn't it taken off? By Marion Renault [330x400-00] Biotech 4 food allergy immunotherapy companies to watch By Maddie Bender Wall Street Hospital A STAT Investigation How America's largest Catholic hospital system is moonlighting as a private equity firm By Rachel Cohrs STAT Reporting from the frontiers of health and medicine Trending: * Coronavirus * Health * First Opinion * Biotech * Pharmalot * Pharma Back to top Company * About * Our Team * Contact Us * Work at STAT * Internships at STAT * Pitch STAT * STAT's Diversity and Inclusion Committee * Sharon Begley-STAT Science Reporting Fellowship * Awards * Contribute * Licensing Stories STAT+ * Learn More * FAQs * Subscribe * Log In * Billing * Help Group Subscriptions * Request A Quote * Contact Us Advertising * Download Media Kit * Advertise With Us Apps & Media * Newsletters * STAT App * Podcasts * STAT Reports * STAT Madness * STAT Wunderkinds Events * STAT Events * Industry Events Calendar * Sponsor Our Events * Privacy * Comment Policy * Terms * Do Not Sell my Data * (c)2021 STAT * * * * * * *